Date Title Description PDF
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download

Pages

Date Title Description PDF
03 Nov 2021 On business and financial situation The Company releases the first nine months 2021 financial results presentation Download
03 Nov 2021 On business and financial situation The Company releases the press release related to the first nine months 2021 financial results Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
21 Oct 2021 Liquidity and counterparty agreements Download
07 Oct 2021 Liquidity and counterparty agreements Download

Pages

Date Title Description PDF
10 May 2018 Otros sobre negocio y situación financiera Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) Download
25 Apr 2018 Información sobre resultados ROVI releases the press release related to the 2018 first quarter financial results Download
25 Apr 2018 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting Download
25 Apr 2018 Información sobre resultados ROVI releases the 2018 first quarter results presentation Download
04 Apr 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2018 Download

Pages